TY  - GEN
AU  - Furlong,Fiona
AU  - Fitzpatrick,Patricia
AU  - O'Toole,Sharon
AU  - Phelan,Sine
AU  - McGrogan,Barbara
AU  - Maguire,Aoife
AU  - O'Grady,Anthony
AU  - Gallagher,Michael
AU  - Prencipe,Maria
AU  - McGoldrick,Aloysius
AU  - McGettigan,Paul
AU  - Brennan,Donal
AU  - Sheils,Orla
AU  - Martin,Cara
AU  - W Kay,Elaine
AU  - O'Leary,John
AU  - McCann,Amanda
TI  - Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer
SN  - 1096-9896
PY  - 2012///0427
KW  - 3' Untranslated Regions
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Biomarkers, Tumor
KW  - genetics
KW  - Calcium-Binding Proteins
KW  - Carboplatin
KW  - administration & dosage
KW  - Carcinoma, Ovarian Epithelial
KW  - Cell Cycle Proteins
KW  - Cell Line, Tumor
KW  - Chemotherapy, Adjuvant
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Down-Regulation
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Humans
KW  - Immunohistochemistry
KW  - Kaplan-Meier Estimate
KW  - Mad2 Proteins
KW  - MicroRNAs
KW  - metabolism
KW  - Multivariate Analysis
KW  - Neoplasm Grading
KW  - Neoplasm Staging
KW  - Neoplasms, Cystic, Mucinous, and Serous
KW  - Neoplasms, Glandular and Epithelial
KW  - drug therapy
KW  - Ovarian Neoplasms
KW  - Paclitaxel
KW  - Paraffin Embedding
KW  - Proportional Hazards Models
KW  - RNA Interference
KW  - Repressor Proteins
KW  - Retrospective Studies
KW  - Risk Assessment
KW  - Risk Factors
KW  - Time Factors
KW  - Transfection
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1002/path.3035
ER  -